- •
Biologics represent a wide range of products that often target immune system pathways resulting in unintended consequences, including infectious events.
- •
Tumor necrosis factor-α inhibitors in pediatric patients may have a differential infection risk based on the agent and underlying condition being treated.
- •
Emerging data on infections specific to biologic administration in pediatrics will be essential to determine the risks of these agents in the future.
Infections in Children on Biologics
Section snippets
Key points
Tumor Necrosis Factor-α Inhibitors
Tumor necrosis factor (TNF)-α, a cell-signaling protein produced acutely by macrophages and monocytes, activates the vascular endothelium and increases vascular permeability. TNF-α inhibitors block the signaling to reduce acute inflammation in patients with RA, juvenile idiopathic arthritis (JIA), various types of psoriasis, and IBD, such as Crohn disease (CD) and ulcerative colitis (UC). Infliximab (CD), adalimumab (CD, JIA), and etanercept (JIA, plaque psoriasis) currently have approved
Summary
Biologic agents target specific pathways to treat immune-mediated diseases, and the use of biologics has expanded exponentially. Pediatric use continues to develop with new indications and emergence of new targets. Epidemiologic data reporting infection-related complications of biologics in pediatric patients are limited, but current data suggest that differences in types of pathogens exist relative to the pathways targeted by the agents. Further reporting of infectious events associated with
Acknowledgments
The author acknowledges Grant Paulsen, MD for his careful review of this article.
References (61)
- et al.
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
Lancet
(2015) Tumor necrosis factor blockade: mechanism of action
J Investig Dermatol Symp Proc
(2007)- et al.
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Gastroenterology
(2007) - et al.
Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review
Clin Gastroenterol Hepatol
(2014) - et al.
Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - a systematic review of randomized trials, observational studies and case reports
Vaccine
(2017) - et al.
Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies
Rev Bras Reumatol
(2016) - et al.
Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression
Am J Transplant
(2006) - et al.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet
(2015) - et al.
Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients
Biol Blood Marrow Transplant
(2017) - et al.
Tofacitinib for the treatment of alopecia areata and variants in adolescents
J Am Acad Dermatol
(2017)
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients
Am J Transplant
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Blood
Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida
Int J Dermatol
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
N Engl J Med
Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)
JAMA Dermatol
Fatal group A Streptococcus purpura fulminans in a child receiving TNF-alpha blocker
Eur J Pediatr
Listeria meningitis after infliximab treatment of ulcerative colitis
J Pediatr Gastroenterol Nutr
Systemic Mycobacterium avium complex infection during antitumor necrosis factor-alpha therapy in pediatric Crohn disease
J Pediatr Gastroenterol Nutr
Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series
Inflamm Bowel Dis
Atypical cutaneous blastomycosis in a child with juvenile idiopathic arthritis on infliximab
Pediatrics
Incidence of herpes zoster infections in juvenile idiopathic arthritis patients
Rheumatol Int
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis
J Am Acad Dermatol
Risk of tuberculosis in children with juvenile idiopathic arthritis: a nationwide population-based study in Taiwan
PLoS One
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment
Arthritis Rheum
Tuberculosis in pediatric patients treated with anti-TNFalpha drugs: a cohort study
Pediatr Rheumatol Online J
Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry
Arthritis Care Res
Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: retrospective, multicenter studies
Adv Clin Exp Med
Seroprevalence of Epstein-Barr virus, cytomegalovirus, and polyomaviruses in children with inflammatory bowel disease
Dig Dis Sci
Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab
Am J Gastroenterol
Cited by (0)
Disclosures: No relationships to report.